Further to the announcement made on 13 September 2018, Scapa Group plc (AIM: SCPA) is pleased to announce that its acquisition of the share capital of Systagenix Wound Management Manufacturing Limited completed on 1 October 2018. In addition, Scapa and Acelity have now entered into the exclusive five-year manufacturing and supply agreement for Systagenix advanced wound care products that are currently manufactured in the Gargrave facility, with immediate effect.
Back to All News
All Market News
Other Market News
Finsbury Growth & Income Trust – Half-Year Report
Watkin Jones Release Half Year Results
Softcat Release Q3 2025 Trading Update
GlobalData – Rule 2.8 Announcement
GlobalData – Extension of Rule 2.6 Deadline
AstraZeneca Release Imfinzi Update
Sign up for our Stock News Highlights
Delivered to your inbox every Friday